WallStSmart

Stryker Corporation (SYK)vsZimmer Biomet Holdings Inc (ZBH)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Stryker Corporation generates 205% more annual revenue ($25.12B vs $8.23B). SYK leads profitability with a 12.9% profit margin vs 8.6%. ZBH appears more attractively valued with a PEG of 0.60. SYK earns a higher WallStSmart Score of 65/100 (C+).

SYK

Buy

65

out of 100

Grade: C+

Growth: 8.0Profit: 7.5Value: 9.3Quality: 7.0
Piotroski: 3/9Altman Z: 2.18

ZBH

Buy

59

out of 100

Grade: C

Growth: 4.7Profit: 5.5Value: 7.3Quality: 6.3
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

SYKUndervalued (+16.8%)

Margin of Safety

+16.8%

Fair Value

$393.59

Current Price

$327.65

$65.94 discount

UndervaluedFair: $393.59Overvalued
ZBHSignificantly Overvalued (-296.1%)

Margin of Safety

-296.1%

Fair Value

$24.14

Current Price

$87.64

$63.50 premium

UndervaluedFair: $24.14Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

SYK4 strengths · Avg: 8.8/10
EPS GrowthGrowth
55.9%10/10

Earnings expanding 55.9% YoY

Market CapQuality
$125.72B9/10

Large-cap with strong market position

Operating MarginProfitability
27.2%8/10

Strong operational efficiency at 27.2%

Free Cash FlowQuality
$1.88B8/10

Generating 1.9B in free cash flow

ZBH2 strengths · Avg: 9.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

PEG RatioValuation
0.608/10

Growing faster than its price suggests

Areas to Watch

SYK3 concerns · Avg: 3.7/10
PEG RatioValuation
1.604/10

Expensive relative to growth rate

P/E RatioValuation
39.1x4/10

Premium valuation, high expectations priced in

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

ZBH3 concerns · Avg: 2.7/10
Return on EquityProfitability
5.6%3/10

ROE of 5.6% — below average capital efficiency

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

EPS GrowthGrowth
-40.8%2/10

Earnings declined 40.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : SYK

The strongest argument for SYK centers on EPS Growth, Market Cap, Operating Margin. Revenue growth of 11.4% demonstrates continued momentum.

Bull Case : ZBH

The strongest argument for ZBH centers on Price/Book, PEG Ratio. Revenue growth of 10.9% demonstrates continued momentum. PEG of 0.60 suggests the stock is reasonably priced for its growth.

Bear Case : SYK

The primary concerns for SYK are PEG Ratio, P/E Ratio, Piotroski F-Score.

Bear Case : ZBH

The primary concerns for ZBH are Return on Equity, Piotroski F-Score, EPS Growth.

Key Dynamics to Monitor

SYK carries more volatility with a beta of 0.87 — expect wider price swings.

SYK is growing revenue faster at 11.4% — sustainability is the question.

SYK generates stronger free cash flow (1.9B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SYK scores higher overall (65/100 vs 59/100) and 11.4% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Stryker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.

Visit Website →

Zimmer Biomet Holdings Inc

HEALTHCARE · MEDICAL DEVICES · USA

Zimmer Biomet is a publicly traded medical device company. The company is headquartered in Warsaw, Indiana, where it is part of the medical devices business cluster.

Visit Website →

Want to dig deeper into these stocks?